Abstract: Objective To evaluate the clinical efficacy of TACE and radiofrequency ablation（RFA） in treatment of patients with primary liver cancer（PLC）. Methods Sixty patients with PLC in the center of liver diseases in our hospital between April 2012 and March 2013 were randomly divided into two groups,with 30 cases in each group,and the patients were given RFA after TACE or TACE alone therapy. The short-and long-term clinical response were compared. Results There was no significant difference at baseline between the two groups as respect to gender,age,hepatitis B surface antigen positive,liver function index,α-fetoprotein （AFP）,tumor numbers and tumor diameters（P>0.05）;the complete and partial remission rates in the combination group（26.7% and 50.0%,respectively）were much higher than those（6.7% and 23.3%,respectively）in the TACE group （P<0.05）;the survival periods in the combination group（2.86±0.48 years）was much longer than that （0.93±0.27 years）in the TACE group（P<0.05）;serum AFP level at the end of first,second and third year after treatment in the combination group[（475.4±200.7） μg/L,（416.4±229.0） μg/L and （320.4±243.5） μg/L] were lower than those [（639.1±190.9） μg/L,（623.4±234.6） μg/L and（674.4±300.2 ）μg/L] in TACE group （P<0.05）;the 1 a,2 a and 3 a survival rates after treatment in the combination group（86.7%,66.7% and 56.7%） were significantly higher than those（46.7%,26.7% and 10.0%）in the TACE group（P<0.05）. Conclusion Combination of TACE and RFA has a remarkable clinical efficacy for patients with PLC,which is worthy of further investigation.

Key words: Hepatoma, Transcatheter arterial chemoembolization, Radiofrequency ablation, Therapy